肿瘤细胞治疗研究
英文原题：Combined Immune Therapy Proves Effective in an Advanced Hepatocellular Carcinoma Patient With Poor Liver Reserve: A Case Report.
对于体能状态较差且肝脏储备功能有限，被归类为Child-Pugh B级和C级的患者，目前没有有效的治疗选择。
对于体能状态差、肝脏储备功能有限、被归类为Child-Pugh B级和C级的患者，尚无有效的治疗选择。一名61岁男性，既往有丙型肝炎病毒感染史，因腹胀和明显腹水入院。他被诊断为IVB期肝细胞癌（HCC），特征为多发淋巴结、肺和骨转移。在接受联合免疫治疗后，包括靶向WT1和α-半乳糖神经酰胺的树突状细胞疗法、NK 细胞和Nivolumab，患者的HCC和肝脏储备功能显著改善，并接受了标准治疗。联合免疫治疗可能是晚期肝细胞癌且肝脏储备功能差的患者的重要选择，尤其是相对年轻的患者。
There are no effective treatment options for patients with poor performance status and limited liver reserve, classified as Child-Pugh Grade B and C. A 61-year-old man with a prior medical history of hepatitis C virus infection was admitted to the hospital with abdominal distension and significant abdominal ascites. He was diagnosed with stage IVB hepatocellular carcinoma (HCC), characterized by multiple metastases to lymph nodes, lungs, and bones. After receiving combined immune therapy, including dendritic cell therapy targeting WT1 and α-Galactosylceramide, natural killer cells, and Nivolumab, the patient showed significant improvement in HCC and liver reserve function and followed standard treatment. Combined immune therapy is potentially an important option for patients with advanced hepatocellular carcinoma and poor liver reserve function, especially for relatively young patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
